BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Cells\, Proteins and Bioprocessing  - Dr Sophia Karagiannis \, Sen
 ior Research Fellow in Translational Cancer Immunology\, Head of Cancer An
 tibody Discovery and Immunotherapy\, King's College London School of Medic
 ine\, UK
DTSTART:20140617T080000Z
DTEND:20140617T160000Z
UID:TALK51866@talks.cam.ac.uk
CONTACT:Dr Shara Cohen
DESCRIPTION:www.regonline.co.uk/Biopro2014\n\nThis three day event will di
 scuss three main topics\nCell Culture Technology Event: Recent advances\, 
 future prospect\nTherapeutic proteins and antibodies: from design to funct
 ion\nBioprocess development: Discussing facilitation of industrial uptake\
 nWith plenty of opportunity  for networking and debate\, this informal int
 ernational  meeting will bring you up to date with current research and th
 inking. \n\nThis event  has CPD accreditation\n\nWho Should Attend\nAll ac
 ademic and biotechnology/biopharma professionals interested in biological 
 protein and antibody engineering\, functional and potency evaluations\, bi
 ological therapeutics mechanisms of action and translational implications 
 for therapy would find this meeting useful.  Individuals interested in the
  any process that uses complete living cells or their components (e.g.\, b
 acteria\, enzymes\, chloroplasts) to obtain desired products should also a
 ttend this event.\n\nThe deadline for abstract submissions for oral presen
 tation is April 10th 2014.Abstracts for poster presentation only can be su
 bmitted up to two weeks before the event. \n\nYou can download the instruc
 tions for authors at  www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf\nThere wi
 ll be an open poster session\, where posters can be submitted on any subje
 ct related to Cells\, Proteins and Bioprocessing \n\nProgram Outline\n\nDa
 y 1:  Cell Culture Technology Event: Recent advances\, future prospect \nC
 ell culture has matured to become the pivotal technology in biopharmaceuti
 cal research\, development and production\, and its use in this and other 
 areas continues to expand rapidly. In vitro models are replacing animals i
 n many tests and assays\; its enormous potential in the fields of stem cel
 l and regenerative medicine has hardly started to be realized\; its utilit
 y in research grows ever faster. \n\nThis session will examine some of the
  latest applications of cell culture technology\, some that are still “o
 ver the horizon”\, and some of the problems that must be solved before i
 t can reach its full potential.\n\nDay 2:  Therapeutic proteins and antibo
 dies: from design to function\nThis session discusses new developments in 
 therapeutic protein and antibody engineering with specific focus on scienc
 e and technology of modifying proteins and antibodies (and the conditions 
 of their manufacture) toward specific predefined properties that allow the
 m to act as effective biological drugs. Special emphasis will be placed on
  structure-function relationships\, mechanisms of action\, potency and eff
 icacy in disease-relevant models and in clinical trials. There will be ple
 nty of opportunity for discussion and debate addressing the wide range of 
 disciplines applied to the rapid and economical production of these molecu
 les for biological therapies\n\nDay 3:  Bioprocess development: Discussing
  facilitation of industrial uptake.\nThis will focus on recent technologie
 s used in high throughput bioprocess development\, from clone selection th
 rough to analysis of final product and formulation.   Bioprocess miniaturi
 zation\, effective upscaling\, downstream processing and analytics will al
 l be discussed.  Expert speakers will describe the development and use of 
 current technologies together with the  technical and regulatory hurdles t
 hat must be overcome to facilitate wider industrial uptake.\n\n\nTalks Inc
 lude:\n\nMicro-cariers: its role in reducing the cost\, time\, and efforts
  towards industrial cells proliferation and protein productions\nDr Ali Hi
 lal-Alnaqbi\, Assistant Professor UAEU\, Visiting Assistant Professor\, Ha
 rvard\, USA\n\nTherapeutic IgE antibodies: enhanced effector functions for
  cancer therapy\nDr Sophia Karagiannis \, Senior Research Fellow in Transl
 ational Cancer Immunology\, Head of Cancer Antibody Discovery and Immunoth
 erapy\, King's College London School of Medicine\, UK\n\nIntroducing a Nov
 el liquid 3 Dimensional Scaffold for Culturing Cells in 3D\nDr Anthony Mit
 chell Davies\, Director of INCHSA\, Dept Clinical Medicine Trinity College
  Dublin\, Ireland\n\nQuantum dot- conjugated antibodies as diagnostic and 
 therapeutic tools for cancer imaging and treatment \nDr Weiming Xu\, CEO\,
  London Biotech Ltd\, UK\n\nReal time\, label-free characterisation of liv
 e cells in monolayer culture using high resolution\, multi-modal light mic
 roscopy\nDr Melissa Mather\, Principal Research Fellow\, Institute of Biop
 hysics\, Imaging and Optical Science\, University of Nottingham\, UK\n\nBi
 ofabrication technologies for 3D cell culture systems   \nDr Lorenzo Moron
 i\, Associate Professor\, University of Twente\, Tissue Regeneration Depar
 tment\, The Netherlands\n\nelection of isotype for immunomodulatory anti-c
 ancer antibodies\nDr Ann White\, Senior Research Fellow\, University of So
 uthampton\, UK\n\nDeveloping of long acting glycoprotein hormones using ge
 ne fusion and gene transfer: from bench to clinics\nProfessor. Fuad Fares\
 , University of Haifa\, Israel\n\n3D-tetraculture system mimicking the cel
 lular organization at the alveolar barrier.\nDr Arno C. Gutleb\, Chef de p
 rojet\, Centre de Recherche Public - Gabriel Lippmann\, Luxembourg\n\nProt
 ein based nano and micro particles for biological applications\nDr Deepak 
 Kalaskar UCL \, London\n\nHigh-Throughput and Miniaturisation in Process D
 evelopment\nDr Adrian Haines\, Lonza Biologics plc\, UK\n\nXanthine Oxidas
  and its organ specific forms are the target therapeutics molecules in the
  treatment of stroke\nDr Kristine Danielyan\, Senior Scientific Worker\, T
 eam Leader. H Buniatian Inst of Biochemistry\, National Academy of Science
 \, Yerevan\, Armenia\n\nNew method to identified amino acids\, peptides an
 d transjunctional proteins: Co-culture transwell system and mass spectrome
 try.\nDr. Maria D. Mayan\, Cartilage Biology Research Group\, Rheumatology
  Division\, Biomedical Research Center (INIBIC)\, CH Universitario A Coru
 ña\, Spain\n\nTalk title up be confirmed\nDr. Ajoy Velayudhan \n\nMitocho
 ndrial NAD pooland metastasis\nProf. Maria Luigia Pallotta\, Assistant Pro
 fessor / Researcher in Biochemistry\, Department of Medicine and Health Sc
 iences\, University of Molise\, Campobasso\, Italy\n\nTalk title to be con
 firmed\nDr. Mark Peacock\, Applikon Biotechnology UK\, Basepoint Business 
 Centre\, Oakfield Close\, Tewkesbury Business Park\, Tewkesbury\, Gloucest
 ershire\, GL20 8SD\, UK\nAdditional Speakers Include\nDr Sergio A. Quezada
 \, Immune Regulation and Tumour Immunotherapy Group\, UCL Cancer Institute
 \, UK\nDr Miriam Dwek\, University of Westminster\, UK
LOCATION:Cineworld: The O2\, Peninsula Square\, London\, SE10 0DX
END:VEVENT
END:VCALENDAR